Brightlands Venture Partners
Brightlands Venture Partners is an independent venture capital firm based in Geleen, Netherlands, founded in 2014. The firm focuses on investing in sectors such as renewable chemistry, circularity, regenerative medicine, biomedical materials, agritech, food, and digital technologies. As an ecosystem investor, Brightlands Venture Partners primarily seeks opportunities in companies linked to the Brightlands campuses, fostering innovation within the region. The firm manages several funds, including Limburg Ventures, Chemelot Ventures, and Brightlands Agrifood Fund, which are largely privately funded but supplemented with public financing to enhance their investment capacity. The firm emphasizes environmental, social, and governance (ESG) criteria in its investment strategy and aims to support companies that drive positive impact in their respective fields.
Matisse Pharmaceuticals
Venture Round in 2024
Matisse Pharmaceuticals B.V. is a biotechnology company based in Geleen, the Netherlands, specializing in the development of pharmaceutical therapies for sepsis and related inflammatory disorders. Founded in 2014, the company is advancing its lead product, M6229, a heparin fraction currently in the pre-clinical phase, aimed at treating severe sepsis and septic shock. Matisse Pharmaceuticals focuses on research and development efforts to create therapies that neutralize harmful components of the inflammatory system, ultimately enhancing treatment options for healthcare professionals and improving patient outcomes.
AVL Motion
Seed Round in 2019
AvL Motion BV, based in Overloon, the Netherlands, specializes in developing autonomous harvesting robots aimed at automating the labor-intensive process of selective crop harvesting. The company's flagship product is a selective asparagus harvester, designed to efficiently harvest white asparagus, with applications also extending to other crops such as green asparagus and zucchini. By introducing advanced technology into horticulture, AvL Motion seeks to enhance industrial automation within the agricultural sector, allowing small and medium-sized enterprises to benefit from improved labor efficiency and process optimization.
Hy2Care BV is a start-up based at the University of Twente in the Netherlands, focused on developing a groundbreaking treatment for osteoarthritis, a condition affecting over 100 million patients in the Western world. The company's primary product is an injectable hydrogel, designed to repair cartilage defects, particularly in the knee. This bioresorbable hydrogel consists of a two-component system made from natural polymer conjugates that undergo a mild enzymatic reaction to create a functional repair solution for cartilage damage. Hy2Care aims to significantly improve the quality of life for individuals suffering from osteoarthritis by providing an effective and innovative treatment option.
Hy2Care BV is a start-up based at the University of Twente in the Netherlands, focused on developing a groundbreaking treatment for osteoarthritis, a condition affecting over 100 million patients in the Western world. The company's primary product is an injectable hydrogel, designed to repair cartilage defects, particularly in the knee. This bioresorbable hydrogel consists of a two-component system made from natural polymer conjugates that undergo a mild enzymatic reaction to create a functional repair solution for cartilage damage. Hy2Care aims to significantly improve the quality of life for individuals suffering from osteoarthritis by providing an effective and innovative treatment option.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.